S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
66,000% upside on tiny biotech? (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
66,000% upside on tiny biotech? (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
66,000% upside on tiny biotech? (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
66,000% upside on tiny biotech? (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

$2.83
-0.04 (-1.39%)
(As of 02/23/2024 ET)
Today's Range
$2.81
$2.87
50-Day Range
$2.58
$3.23
52-Week Range
$1.46
$4.75
Volume
21,351 shs
Average Volume
36,738 shs
Market Capitalization
$107.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

DiaMedica Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.3% Upside
$7.00 Price Target
Short Interest
Healthy
0.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.61) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.89 out of 5 stars

Medical Sector

819th out of 941 stocks

Pharmaceutical Preparations Industry

382nd out of 437 stocks


DMAC stock logo

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Stock Price History

DMAC Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Q3 2023 DiaMedica Therapeutics Inc Earnings Call
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Earnings Outlook For DiaMedica Therapeutics
Q2 2023 DiaMedica Therapeutics Inc Earnings Call
See More Headlines
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2023
Today
2/24/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+147.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.20 per share

Miscellaneous

Free Float
35,487,000
Market Cap
$107.40 million
Optionable
Optionable
Beta
1.70
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Dietrich John Pauls MBAMr. Dietrich John Pauls MBA (Age 53)
    President, CEO & Director
    Comp: $736.79k
  • Mr. Scott Kellen CPA (Age 59)
    CFO & Company Secretary
    Comp: $447.02k
  • Dr. Kirsten L. Gruis M.D. (Age 51)
    M.S., Independent Consultant
    Comp: $519.82k
  • Dr. Ambarish Shah Ph.D.
    Chief Technology Officer
  • Mr. Dominic R. Cundari (Age 73)
    Chief Commercial Officer
  • Ms. Julie VanOrsdel Daves CCRP
    Senior VP of Clinical Development Operations
  • Mr. David J. Wambeke
    Chief Business Officer
  • Dr. Lorianne K. Masuoka M.D. (Age 63)
    Chief Medical Officer














DMAC Stock Analysis - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued twelve-month target prices for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 147.3% from the stock's current price.
View analysts price targets for DMAC
or view top-rated stocks among Wall Street analysts.

How have DMAC shares performed in 2024?

DiaMedica Therapeutics' stock was trading at $2.84 on January 1st, 2024. Since then, DMAC shares have decreased by 0.4% and is now trading at $2.83.
View the best growth stocks for 2024 here
.

When is DiaMedica Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our DMAC earnings forecast
.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its earnings results on Tuesday, March, 28th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). During the same period last year, the business posted ($0.10) EPS.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.11%), Paragon Associates & Paragon Associates II Joint Venture (1.32%), Northern Trust Corp (0.35%), Avantax Advisory Services Inc. (0.03%), Simplex Trading LLC (0.00%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David J Wambeke, Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends
.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DMAC) was last updated on 2/24/2024 by MarketBeat.com Staff